About Guanine nucleotide-binding protein G(o) subunit alpha
Guanine nucleotide-binding protein G(o) subunit alpha (GNAO1) is a protein
from Homo sapiens identified by UniProt accession
P09471, 354 residues long.
MolForge cross-references it against 0 known binders and
298 disease associations.
Target properties
| Protein name | Guanine nucleotide-binding protein G(o) subunit alpha |
| UniProt accession | P09471 |
| Gene | GNAO1 |
| Organism | Homo sapiens |
| Length | 354 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (298)
Diseases linked to this target (Open Targets).
- neurodevelopmental disorder with involuntary movements · score 0.80
- developmental and epileptic encephalopathy · score 0.70
- Epileptic encephalopathy · score 0.66
- genetic disorder · score 0.53
- movement disorder · score 0.45
- Abnormality of the nervous system · score 0.43
- insomnia measurement · score 0.41
- chronotype measurement · score 0.39
- wellbeing measurement · score 0.37
- diastolic blood pressure · score 0.37
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P09471-F1 | alphafold | PREDICTED | 94.52 | — |
Amino-acid sequence (354 residues)
MGCTLSAEER AALERSKAIE KNLKEDGISA AKDVKLLLLG AGESGKSTIV KQMKIIHEDG FSGEDVKQYK PVVYSNTIQS LAAIVRAMDT LGIEYGDKER KADAKMVCDV VSRMEDTEPF SAELLSAMMR LWGDSGIQEC FNRSREYQLN DSAKYYLDSL DRIGAADYQP TEQDILRTRV KTTGIVETHF TFKNLHFRLF DVGGQRSERK KWIHCFEDVT AIIFCVALSG YDQVLHEDET TNRMHESLML FDSICNNKFF IDTSIILFLN KKDLFGEKIK KSPLTICFPE YTGPNTYEDA AAYIQAQFES KNRSPNKEIY CHMTCATDTN NIQVVFDAVT DIIIANNLRG CGLY
Explore Guanine nucleotide-binding protein G(o) subunit alpha with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets